With Proposed Sale of Clontech, BD Set To Focus Solely on Cellular Analysis | GenomeWeb

Becton Dickinson on Monday said it plans to sell its Clontech business unit, putting on the sales block one of the most recognized brand assets in the molecular biology tools market.

The Franklin Lakes, NJ-based BD said it has retained Goldman Sachs to manage the deal and plans to take a $125 million pre-tax charge contingent upon completion of any sale of Clontech, a company acquired for $201 million in 1999. Clontech has 220 employees.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.